Index: Original Cancer Costing Research Using Canadian Data

Vol 23 (2016)
 

Table of Contents

Editorial(s)

Original Canadian cancer costing research for cancer control sustainability, quality, and value H. Bryant

PDF HTML S5

Importance of cost estimates and cost studies N. Mittmann, C. de Oliveira

PDF HTML S6

Original Article(s)

Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada P.A. Tang, A.E. Hay, C.J. O’Callaghan, N. Mittmann, C.R. Chambers, J.L. Pater, N.B. Leighl

PDF HTML S7-S13

Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis I. Cromwell, Z. Ferreira, L. Smith, K. van der Hoek, G. Ogilvie, A. Coldman, S.J. Peacock

PDF HTML S14-S22

Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservation N.J. Look Hong, G.M. Clarke, M.J. Yaffe, C.M.B. Holloway

PDF HTML S23-S31

Population-based trends in systemic therapy use and cost for cancer patients in the last year of life R.E. Pataky, W.Y. Cheung, C. de Oliveira, K.E. Bremner, K.K.W. Chan, J.S. Hoch, M.D. Krahn, S.J. Peacock

PDF HTML S32-S41

Temporal association between home nursing and hospital costs at end of life in three provinces H. Seow, R. Pataky, B. Lawson, E.M. O'Leary, R. Sutradhar, K. Fassbender, K. McGrail, L. Barbera, F. Burge, S.J. Peacock, J.S. Hoch

PDF HTML S42-S51

Cost implications of unwarranted imaging for distant metastasis in women with early-stage breast cancer in Ontario K. Thavorn, Z. Wang, D. Fergusson, S. van Katwyk, A. Arnaout, M. Clemons

PDF HTML S52-S55

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada C. Popadiuk, C.L. Gauvreau, M. Bhavsar, C. Nadeau, K. Asakawa, W.M. Flanagam, M.C. Wolfson, A.J. Coldman, S. Memon, N. Fitzgerald, J. Lacombe, A.B. Miller

PDF HTML S56-S63

Cost trajectories for cancer patients W.P Wodchis, E. Arthurs, A.I. Khan, S. Gandhi, M. MacKinnon, J. Sussman

PDF HTML S64-S75

Angle PLC Announces Initiation of 200 Patient European Ovarian Cancer Study (Parsortix™)

press release

DNA Mismatch Repair Deficiency in Rectal Cancer (MSH2/6)

abstract:
DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics

 Five of the 11 (45.5%) deaths during follow-up were due to extracolorectal malignancies

Pharmacists: Integral to the Management of Chemotherapy-Induced Nausea and Vomiting (ASCO/article/response)

Pharmacists: Integral to the Management of Chemotherapy-Induced Nausea and Vomiting

To the Editor:

We are surprised that the recently updated ASCO antiemetic guideline excludes pharmacists as a targeted audience.¹

 REFERENCES

1. 1.↵
   1. Hesketh PJ,
   2. Bohlke K,
   3. Lyman GH,
   4. et al.

   (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381–386.

   Abstract/FREE Full Text
2. 2.↵
   National Comprehensive Cancer Network: Antiemesis, version 2.2015. Jenkintown, PA, National Comprehensive Cancer Network, 2015.
3. 3.↵
   Cancer Care Ontario Antiemetic Working Group: Antiemetic report: Clinical evidence for recommendations. Toronto, Ontario, Canada, Cancer Care Ontario, 2013.
4. 4.↵
   1. Lee Dupuis L,
   2. Robinson PD,
   3. Boodhan S,
   4. et al.

   (2014) Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients (Pediatric Oncology Group of Ontario, Toronto, Ontario, Canada).

   Google Scholar
5. 5.↵
   American Society of Clinical Oncology: The state of cancer care in America, 2014: A report by the American Society of Clinical Oncology. J Oncol Pract 10:119-142, 2014.

Related Article

• CORRESPONDENCE: Reply to J. Jupp et al

  • Paul J. Hesketh,
  • Kari Bohlke,
  • and Mark G. Kris

  JCO JCO686147; published online on July 18, 2016;
  • [Full Text]
  • [PDF]

Article/Correspondence: Symptom monitoring with patient-reported outcomes during routine cancer treatment

CORRESPONDENCE Symptom Improvement Requires More Than Screening and Feedback

• Kurt Kroenke and
• Andrea Lynne Cheville

JCO published online on July 18, 2016; DOI:10.1200/JCO.2016.67.7708.

• [Full Text]
• [PDF]

CORRESPONDENCE Reply to K. Kroenke et al

• Ethan Basch

JCO published online on July 18, 2016; DOI:10.1200/JCO.2016.67.9480.

• [Full Text]
• [PDF] 
•  
  

  REFERENCES

• 1.↵
  1. Kroenke K,
  2. Cheville AL

  Symptom improvement requires more than screening and feedback. J Clin Oncol, doi:10.1200/JCO.2016.67.7708.
• 2.↵
  1. Basch E,
  2. Deal AM,
  3. Kris MG,
  4. et al.

  (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol 34:557–565.

  Abstract/FREE Full Text

8th Edition UICC TNM Classification Tumours Jan 2017 Ovary, FT, PP

2014/2016 TNM and Ovary, Fallopian Tube and primary peritoneal carcinoma FIGO